{
    "id": "dbpedia_324_2",
    "rank": 54,
    "data": {
        "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/references",
        "read_more_link": "",
        "language": "en",
        "title": "Vaccines for preventing influenza in healthy children - Jefferson, T - 2018",
        "top_image": "https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png",
        "meta_img": "https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png",
        "images": [
            "https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png",
            "https://www.cochranelibrary.com/scolaris-search/icon.png",
            "https://www.cochranelibrary.com/scolaris-language-portlet/icon.png",
            "https://www.cochranelibrary.com/scolaris-language-portlet/icon.png",
            "https://www.cochranelibrary.com/scolaris-content-display/icon.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-04.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-05.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-06.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-07.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-08.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-04.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-05.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-003-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-003-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-004-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-004-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-04.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-05.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-06.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-07.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-08.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-09.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-10.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-11.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-006-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-006-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-006-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-007-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-007-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-008-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-008-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-008-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-AFig-FIG01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-AFig-FIG02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-04.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-05.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-06.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-07.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-001-08.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-04.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-002-05.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-003-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-003-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-004-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-004-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-04.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-05.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-06.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-07.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-08.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-09.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-10.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-005-11.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-006-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-006-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-006-03.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-007-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-007-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-008-01.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-008-02.png",
            "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004879.pub5/media/CDSR/CD004879/image_n/nCD004879-CMP-008-03.png",
            "https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png",
            "https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png",
            "https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png",
            "https://www.cochranelibrary.com/scolaris-search/icon.png",
            "https://www.cochranelibrary.com/scolaris-language-portlet/icon.png",
            "https://www.cochranelibrary.com/cochrane-theme/images/spacer.png",
            "https://www.cochranelibrary.com/scolaris-content-display/icon.png",
            "https://www.cochranelibrary.com/cochrane-theme/images/spacer.png",
            "https://www.cochranelibrary.com/scolaris-content-display/icon.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Tom Jefferson",
            "Alessandro Rivetti",
            "Carlo Di Pietrantonj",
            "Vittorio Demicheli"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.cochranelibrary.com/web/cochrane/content?templateType=references&urlTitle=/cdsr/doi/10.1002/14651858.CD004879.pub5&doi=10.1002/14651858.CD004879.pub5&type=cdsr&contentLanguage=",
        "text": "Vaccines for preventing influenza in healthy children\n\nCollapse all Expand all\n\nReferences\n\nReferences to studies included in this review\n\nJump to:\n\nAlexandrova GI, Budilovsky GN, Koval TA, Polezhaev FI, Garmashova LM, Ghendon YuZ, et al. Study of live recombinant cold‐adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 1986;4(2):114‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold‐adapted, trivalent, intranasal influenza virus vaccine in children. New England Journal of Medicine 1998;338(20):1405‐12. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nPiedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, et al. Safety of the trivalent, cold‐adapted influenza vaccine in preschool‐aged children. Pediatrics 2002;110(4):662‐72. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold‐adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. Journal of Pediatrics 2000;136(2):168‐75. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nPiedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, et al. Safety of the trivalent, cold‐adapted influenza vaccine in preschool‐aged children. Pediatrics 2002;110(4):662‐72. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBeutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase‐specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. Journal of Infectious Diseases 1979;140(6):844‐50. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBeutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase‐specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. Journal of Infectious Diseases 1979;140(6):844‐50. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine‐naive children. Pediatric Infectious Disease Journal 2009;28(5):365‐71. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine‐naive children. Pediatric Infectious Disease Journal 2009;28(5):365‐71. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBrooks WA, Zaman K, Lewis KD, Ortiz JR, Goswami D, Feser J, et al. Efficacy of a Russian‐backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double‐blind, placebo‐controlled trial. Lancet Global Health 2016;4(12):e946‐54. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nClover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83‐like viruses. Journal of Infectious Diseases 1991;163(2):300‐4. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nColombo C, Argiolas L, La Vecchia C, Negri E, Meloni G, Meloni T. Influenza vaccine in healthy preschool children. Revue d'Epidémiologie et de Santé Publique 2001;49(2):157‐62. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nCowling BJ, Ng S, Ma ES, Fang VJ, So HC, Wai W, et al. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clinical Infectious Diseases 2012;55(5):695‐702. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGrigor'eva EP, Desheva I, Donina SA, Naikhin AN, Rekstin AR, Barantseva IB, et al. The comparative characteristics of the safety, immunogenic activity and prophylactic potency of the adult and children types of live influenza vaccine in schoolchildren aged 7‐14 years. Voprosy Virusologii 2002;47(4):24‐7. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nGruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, et al. Live attenuated and inactivated influenza vaccine in school‐age children. American Journal of Diseases in Children 1990;144(5):595‐600. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nHoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003;290(12):1608‐16. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003;290(12):1608‐16. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKhan AS, Polezhaev F, Vasiljeva R, Drinevsky V, Buffington J, Gary H, et al. Comparison of US inactivated split‐virus and Russian live attenuated, cold‐adapted trivalent influenza vaccines in Russian schoolchildren. Journal of Infectious Diseases 1996;173(2):453‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nPrincipi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatric Infectious Disease Journal 2003;22(Suppl 10):207‐10. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nRudenko LG, Grigor'eva EP, Drinevskii VP, Koval' TA, Doroshenko EM. Results of a study of a live intranasal influenza vaccine in the immunization of children 3 to 15 years old. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1988;5:41‐6. CENTRAL\n\nGoogle Scholar\n\nRudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. Journal of Infectious Diseases 1993;168(4):881‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nRudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. Journal of Infectious Diseases 1993;168(4):881‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nRudenko LG, Lonskaya NI, Klimov AI, Vasilieva RI, Ramirez A. Clinical and epidemiological evaluation of a live, cold‐adapted influenza vaccine for 3‐14‐year‐olds. Bulletin of the World Health Organization 1996;74(1):77‐84. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nRudenko LG, Vasil'eva RI, Ismagulov AT, Karagodina VI, Slepushkin AN, Doroshenko EM, et al. Prophylactic effectiveness of a live recombinant influenza type A vaccine in immunizing children aged 3‐14 years. Voprosy Virusologii 1996;41:37‐9. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nTam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold‐adapted influenza vaccine, trivalent against culture‐confirmed influenza in young children in Asia. Pediatric Infectious Disease Journal 2007;26(7):619‐28. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nTam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold‐adapted influenza vaccine, trivalent against culture‐confirmed influenza in young children in Asia. Pediatric Infectious Disease Journal 2007;26(7):619‐28. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nVesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold‐adapted influenza vaccine‐trivalent against community‐acquired, culture‐confirmed influenza in young children attending day care. Pediatrics 2006;118:2298‐312. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nVesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold‐adapted influenza vaccine‐trivalent against community‐acquired, culture‐confirmed influenza in young children attending day care. Pediatrics 2006;118:2298‐312. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nAksenov VA, Selidovkin DA, Sorokina LV, Burnos AS, Sorokina AG. The effectiveness of influenza prevention with a special variation of live influenza vaccine for children in the 1969 epidemic. Voprosy Virusologii 1971;16:81‐6. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Swierkosz EM, Anderson EL, Newman FK, Nugent SL, Maassab HF. Immunization of infants and young children with live attenuated trivalent cold‐recombinant influenza A H1N1, H3N2, and B vaccine. Journal of Infectious Diseases 1992;165(4):727‐32. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nDesheva I, Danini GV, Grigor'eva EP, Donina SA, Kiseleva IV, Rekstin AR, et al. The investigation of the safety, genetic stability and immunogenicity of live influenza vaccine for adults in vaccination of 3‐6 year old children. Voprosy Virusologii 2002;47(4):21‐4. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nGrigor'eva EP, Rekstin AR, Rudenko LG, Ramirez A, Barro M, Lisovskaia KV, et al. The immunogenic properties and prophylactic efficacy of a live polyvalent influenza vaccine in children 5 to 14 years old. Voprosy Virusologii 1994;39(1):26‐9. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nGruber WC, Belshe RB, King JC, Treanor JJ, Piedra PA, Wright PF, et al. Evaluation of live attenuated influenza vaccines in children 6‐18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth‐Ayerst ca Influenza Vaccine Investigators Group. Journal of Infectious Diseases 1996;173(6):1313‐9. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nGruber WC, Darden PM, Still JG, Lohr J, Reed G, Wright PF. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose‐response. Vaccine 1997;15(12‐3):1379‐84. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGutman LT, Wilfert CM, Idriss ZH, Schmidt E, Andrews S, Katz SL. Single‐dose trials of monovalent A/New Jersey/76 (Hsw1N1) influenza virus vaccine in children in Durham, North Carolina. Journal of Infectious Diseases 1977;136(Suppl):575‐8. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nKing JC, Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, et al. Safety and immunogenicity of low and high doses of trivalent live cold‐adapted influenza vaccine administered intranasally as drops or spray to healthy children. Journal of Infectious Diseases 1998;17(5):1394‐7. CENTRAL\n\nGoogle Scholar\n\nLevine MM, Hughes TP, Simon P, O'Donnell S, Grauel S, Levine SG. Monovalent inactivated A/New Jersey/8/76 (Hsw1N1) vaccine in healthy children aged three to five years. Journal of Infectious Diseases 1977;136(Suppl):571‐4. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 2010;5(10):e13755. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nObrosova‐Serova NP, Slepushkin AN, Kendal AP, Harmon MW, Burtseva EI, Bebesheva NI, et al. Evaluation in children of cold‐adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild‐type B/Ann Arbor/1/86 and cold‐adapted B/Leningrad/14/55 viruses. Vaccine 1990;8(1):57‐60. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nPlennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, et al. Influenza A (H1N1) 2009 two‐dose immunization of US children: an observer‐blinded, randomized, placebo‐controlled trial. Vaccine 2011;29(8):1569‐75. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nRudenko LG, Ramirez A, Barro M, Gushchina MI, Armanda RE, Ermachenko TA, et al. The inoculation properties of live recombinant influenza vaccine types A and B used separately and jointly in children 3 to 14. Voprosy Virusologii 1991;36(6):472‐4. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nSlepushkin AN, Dukova VS, Kalegaeva VA, Kagan AN, Temriuk EE. Results of studying the effectiveness of a live influenza vaccine for peroral use on preschool and schoolchildren. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1974;12:24‐9. CENTRAL\n\nGoogle Scholar\n\nSlepushkin AN, Patriarca PA, Obrosova‐Serova NP, Harmon MW, Kupryashina LN, Cheshik SG, et al. Class‐specific antibody responses in school children vaccinated with an A/Brazil/11/78 (H1N1)‐like recombinant influenza virus prepared from the A/Leningrad/134/57 paediatric cold‐adapted donor strain. Vaccine 1988;6(1):25‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSlepushkin AN, Obrosova‐Serova NP, Burtseva EI, Govorkova EA, Rudenko LG, Vartanian RV, et al. A comparative study of the inoculation properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8‐ to 15‐year‐old children. Voprosy Virusologii 1991;36(5):372‐4. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nSteinhoff MC, Halsey NA, Wilson MH, Burns BA, Samorodin RK, Fries LF, et al. Comparison of live attenuated cold‐adapted and avian‐human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children. Journal of Infectious Diseases 1990;162(2):394‐401. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSteinhoff MC, Halsey NA, Fries LF, Wilson MH, King J, Burns BA, et al. The A/Mallard/6750/78 avian‐human, but not the A/Ann Arbor/6/60 cold‐adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. Journal of Infectious Diseases 1991;163(5):1023‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSwierkosz EM, Newman FK, Anderson EL, Nugent SL, Mills GB, Belshe RB. Multidose, live attenuated, cold‐recombinant, trivalent influenza vaccine in infants and young children. Journal of Infectious Diseases 1994;169(5):1121‐4. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nVasil'eva RI, Merkur'eva LA, Latsenko VG, Vasil'eva AM, Shvager MM. Characteristics of the clinical and immunologic safety of inactivated influenza vaccines in children undergoing multiple immunizations. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1988;11:65‐9. CENTRAL\n\nGoogle Scholar\n\nVasil'eva RI, Smirnova LA, Rudenko LG, Drinevskii VP, Tsaritsina IM. The results of state trials of inactivated influenza vaccines for children. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1988;3:49‐54. CENTRAL\n\nGoogle Scholar\n\nWright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. Journal of Pediatrics 1976;88(1):31‐5. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nZangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, Chiu CY, et al. Prospective, randomized, placebo‐controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatic Infectious Disease Journal 2001;20(8):740‐6. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nEffectiveness of vaccine against medical consultation due to laboratory‐confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004‐2005. Canada Communicable Disease Report 2005;31(18):181‐91. CENTRAL\n\nPubMed\n\nCochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory‐confirmed influenza in infants: a matched case control study. Human Vaccines 2010;6(9):729‐35. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nCochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory‐confirmed influenza in infants: a matched case control study. Human Vaccines 2010;23(6):729‐35. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nCochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory‐confirmed influenza in infants: a matched case control study. Human Vaccines 2010;23(6):729‐35. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nEisenberg KW, Szilagyi PG, Fairbrother G, Griffin MR, Staat M, Shone LP, et al. Vaccine effectiveness against laboratory‐confirmed influenza in children 6 to 59 months of age during the 2003‐2004 and 2004‐2005 influenza seasons. Pediatrics 2008;122(5):911‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nEisenberg KW, Szilagyi PG, Fairbrother G, Griffin MR, Staat M, Shone LP, et al. Vaccine effectiveness against laboratory‐confirmed influenza in children 6 to 59 months of age during the 2003‐2004 and 2004‐2005 influenza seasons. Pediatrics 2008;122(5):911‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGilca R, Deceuninck G, De Serres G, Boulianne N, Sauvageau C, Quach C, et al. Effectiveness of pandemic H1N1 vaccine against influenza‐related hospitalization in children. Pediatrics 2011;128(5):e1084‐91. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHirota Y, Takeshita S, Ide S, Kataoka K, Ohkubo A, Fukuyoshi S, et al. Various factors associated with the manifestation of influenza‐like illness. International Journal of Epidemiology 1992;21(3):574‐82. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKelly H, Jacoby P, Dixon GA, Carcione D, Williams S, Moore HC, et al. Vaccine effectiveness against laboratory‐confirmed influenza in healthy young children: a case‐control study. Pediatric Infectious Disease Journal 2011;30(2):107‐11. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I‐MOVE multi‐centre case control study 2010‐11: overall and stratified estimates of influenza vaccine effectiveness in Europe. Eurosurveillance 2011;6(11):19818. CENTRAL\n\nGoogle Scholar\n\nMahmud S, Hammond G, Elliott L, Hilderman T, Kurbis C, Caetano P, et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory‐confirmed H1N1 infections: population‐based case‐control study. Vaccine 2011;29(45):7975‐81. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nStaat MA, Griffin MR, Donauer S, Edwards KM, Szilagyi PG, Weinberg GA, et al. Vaccine effectiveness for laboratory‐confirmed influenza in children 6‐59 months of age, 2005‐2007. Vaccine 2011;29(48):9005‐11. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nStaat MA, Griffin MR, Donauer S, Edwards KM, Szilagyi PG, Weinberg GA, et al. Vaccine effectiveness for laboratory‐confirmed influenza in children 6‐59 months of age, 2005‐2007. Vaccine 2011;29(48):9005‐11. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nValenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009‐2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I‐MOVE) multicentre case‐control study. PLoS Medicine 2011;8(1):e1000388. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nVan Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville‐Leblanc M, Garceau R, et al. Protective effect of single‐dose adjuvanted pandemic influenza vaccine in children. Influenza and Other Respiratory Viruses 2010;4(4):171‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGoodman MJ, Nordin JD, Harper P, Defor T, Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics 2006;117(5):821‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nAllison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N, et al. Influenza vaccine effectiveness in healthy 6‐ to 21‐month‐old children during the 2003‐2004 season. Journal of Pediatrics 2006;149(6):755‐62. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBurtseva EI, Obrosova‐Serova NP, Govorkova EA, Rudenko LG, Vartanian RV, Beliaev AL, et al. A comparative study of the protective properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8‐ to 15‐year‐old children. Voprosy Virusologii 1991;36(5):375‐7. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nBashliaeva ZA, Sumarokov AA, Nefedova LA, Iaroshevskaia II, Ozeretskovskaia NA. Basic results of a committee trial of the new vaccine Grippovac SE‐AZh. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1986;2:49‐54. CENTRAL\n\nGoogle Scholar\n\nChumakov MP, Boiko VM, Malyshkina LP, Mel'nikova SK, Rodin VI. Results of coded trials of the activity of the trivalent subunit influenza vaccine Grippovak in Moscow kindergartens in December 1983 through the 1st quarter of 1984. Voprosy Virusologii 1987;32(2):175‐83. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nEl'shina GA, Gorbunov MA, Bektimirov TA, Lonskaia NI, Pavlova LI, Nikul'shin AA, et al. The evaluation of the reactogenicity, harmlessness and prophylactic efficacy of Grippol trivalent polymer‐subunit influenza vaccine administered to schoolchildren. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2000;2:50‐4. CENTRAL\n\nGoogle Scholar\n\nFujieda M, Maeda A, Kondo K, Kaji M, Hirota Y. Inactivated influenza vaccine effectiveness in children under 6 years of age during the 2002‐2003 season. Vaccine 2006;24(7):957‐63. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJianping H, Xin F, Changshun L, Bo Z, Linxiu G, Wei X, et al. Assessment of effectiveness of Vaxigrip. Vaccine 1999;17(Suppl 1):57‐8. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nKawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Tsuchimoto T, et al. A prospective, Internet‐based study of the effectiveness and safety of influenza vaccination in the 2001‐2002 influenza season. Vaccine 2003;21(31):4507‐13. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKing JC, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, et al. Effectiveness of school‐based influenza vaccination. New England Journal of Medicine 2006;355:2523‐32. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMaeda T, Shintani Y, Miyamoto H, Kawagoe H, Nakano K, Nishiyama A, et al. Prophylactic effect of inactivated influenza vaccine on young children. Pediatrics International 2002;44(1):43‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMaeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6‐24 months. Pediatrics International 2004;46(2):122‐5. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMaeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6‐24 months. Pediatrics International 2004;46(2):122‐5. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMaeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6‐24 months. Pediatrics International 2004;46(2):122‐5. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nOrtqvist A, Berggren I, Insulander M, De Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A (H1N1)v, in Stockholm County, Sweden. Clinical Infectious Diseases 2011;52(10):1203‐11. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nOzgur SK, Beyazova U, Kemaloglu YK, Maral I, Sahin F, Camurdan AD, et al. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatric Infectious Disease Journal 2006;25(5):401‐4. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSalleras L, Dominguez A, Pumarola T, Prat A, Marcos MA, Garrido P, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza‐related illnesses and its social and economic consequences in children aged 3‐14 years: a prospective cohort study. Vaccine 2006;24(44‐6):6638‐42. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSlobodniuk AV, Romanenko VV, Utnitskaia OS, Motus TM, Pereverzev AV. Influence of multiplicity of immunizations of children with inactivated influenza vaccine on immune response and the effectiveness of protection. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2002;4:36‐9. CENTRAL\n\nGoogle Scholar\n\nSlobodniuk AV, Romanenko VV, Utnitskaia OS, Motus TM, Pereverzev AV. Influence of multiplicity of immunizations of children with inactivated influenza vaccine on immune response and the effectiveness of protection. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2002;4:36‐9. CENTRAL\n\nGoogle Scholar\n\nSlobodniuk AV, Romanenko VV, Utnitskaia OS, Motus TM, Pereverzev AV. Influence of multiplicity of immunizations of children with inactivated influenza vaccine on immune response and the effectiveness of protection. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2002;4:36‐9. CENTRAL\n\nGoogle Scholar\n\nVasil'eva RI, Osidak LV, Bichurina MA, Mukhina LP, Chudina LV. Evaluation of the safety, reactogenicity and antigenic activity of inactivated chromatographic influenza vaccine in school children. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1982;4:96‐8. CENTRAL\n\nGoogle Scholar\n\nWiggs‐Stayner KS, Purdy TR, Go GN, McLaughlin NC, Tryzynka PS, Sines JR, et al. The impact of mass school immunization on school attendance. Journal of School of Nursing 2006;22(4):219‐22. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nYin JK, Lahra MM, Iskander M, Lambert SB, Heron L, Nissen MD, et al. Pilot study of influenza vaccine effectiveness in urban Australian children attending childcare. Journal of Paediatrics and Child Health 2011;47(12):857‐62. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMPA. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations – results of a case inventory study by the MPA in Sweden during 2009–2010. www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport pandermrix 110630.pdf (accessed 10 January 2012). CENTRAL\n\nNicholls S, Carroll K, Crofts J, Ben‐Eliezer E, Paul J, Zambon M, et al. Outbreak of influenza A (H3N2) in a highly‐vaccinated religious community: a retrospective cohort study. Communicable Disease and Public Health 2004;7:272‐7. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nRitzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003‐2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005;116(1):153‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSlepushkin AN, Rudenko LG, Kendal AP, Monto AS, Beliaev AL, Burtseva EI, et al. A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity. Voprosy Virusologii 1994;39:129‐31. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nReferences to studies excluded from this review\n\nJump to:\n\nAmbrose CS, Yi T, Falloon J. An integrated, multi study analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2‐17 years. Influenza and Other Respiratory Viruses 2011;5(6):389‐97. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nAmbrose CS, Wu X, Caspard H, Belshe RB. Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity. Vaccine 2014;32(43):5546‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nAnderson EL, Newman FK, Maassab HF, Belshe RB. Evaluation of a cold‐adapted influenza B/Texas/84 reassortant virus (CRB‐87) vaccine in young children. Journal of Clinical Microbiology 1992;30(9):2230‐4. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nFluMist: an intranasal live influenza vaccine. Medical Letter on Drugs and Therapeutics 2003;45(1163):65‐6. CENTRAL\n\nPubMed\n\nBeare AS, Hobson D, Reed SE, Tyrrell DA. A comparison of live and killed influenza‐virus vaccines. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines. Lancet 1968;2(7565):418‐22. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, et al. Correlates of immune protection induced by live, attenuated, cold‐adapted, trivalent, intranasal influenza virus vaccine. Journal of Infectious Diseases 2000;181(3):1133‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatric Infectious Disease Journal 2000;19(Suppl 5):66‐71. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2‐7 years of age. Vaccine 2008;26(Suppl 4):D10‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et al. Safety of cold‐adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatric Infectious Disease Journal 2004;23(2):138‐44. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBetts RF, Douglas RG, Roth FK, Little JW. Efficacy of live attenuated influenza A/Scotland/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus. Journal of Infectious Diseases 1977;136:746‐53. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBeutner KR, Rizzone C, DeMello S, Ogra PL. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children. Developments in Biological Standardization 1976;33:162‐70. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nBichurina MA, Polianskaia NI, Zhebrun AB, Rozaeva NR, Mukhina LP. Preliminary results of a trial of a highly purified inactivated chromatographic influenza vaccine for children. Trudy Instituta Imeni Pastera 1982;58:14‐6. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nBlock SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double‐blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011;29(50):9391‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBoyce TG, Gruber WC, Coleman‐Dockery SD, Sannella EC, Reed GW, Wolff M, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999;18(1‐2):82‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBoyce TG, Hsu HH, Sannella EC, Coleman‐Dockery SD, Baylis E, Zhu Y. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000;19(2‐3):217‐26. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBoyer KM, Cherry JD, Welliver RC, Deseda‐Tous J, Zahradnik JM, Dudley JP, et al. Clinical trials with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76‐A/Victoria/75) influenza vaccines in Los Angeles children. Journal of Infectious Diseases 1977;136(Suppl):661‐4. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nÇakir BC, Beyazova U, Kemaloğlu YK, Özkan S, Gündüz B, Özdek A. Effectiveness of pandemic influenza A/H1N1 vaccine for prevention of otitis media in children. European Journal of Pediatrics 2012;171(11):1667‐71. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nChow TC, Beutner KR, Ogra PL. Cell‐mediated immune responses to the hemagglutinin and neuraminidase antigens of influenza A virus after immunization in humans. Infection and Immunity 1979;25(1):103‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nClements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6‐ to 30‐month‐old children in day care. Archives of Pediatric and Adolescent Medicine 1995;149(10):1113‐7. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nColes FB, Balzano GJ, Morse DL. An outbreak of influenza A (H3N2) in a well immunized nursing home population. Journal of the American Geriatrics Society 1992;40(6):589‐92. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nCowling BJ, Perera RA, Fang VJ, Chan KH, Wai W, So HC, et al. Incidence of influenza virus infections in children in Hong Kong in a 3‐year randomized placebo‐controlled vaccine study, 2009‐2012. Clinical Infectious Diseases 2014;59(4):517‐24. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nDaubeney P, Taylor CJ, McGaw J, Brown EM, Ghosal S, Keeton BR, et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high‐risk children aged 6 months to 4 years. British Journal of Clinical Practice 1997;51(2):87‐90. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nDonatelli I, Zannolli R, Fuiano L, Biasio LR. Influenza vaccine in immunogenically naive healthy infants. European Journal of Pediatrics 1998;157(11):949‐50. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nEddy TS, Davies NA. The effect of vaccine on a closed epidemic of Hong Kong influenza. South African Medical Journal 1970;44(8):214‐6. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nEdwards KM, Dupont WD, Westrich MK, Plummer WD, Palmer PS, Wright PF. A randomized controlled trial of cold‐adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases 1994;169(1):68‐76. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nEl'shina GA, Gorbunov MA, Shervarli VI, Lonskaia NI, Pavlova LI, Khaitov RM, et al. Evaluation of the effectiveness of influenza trivalent polymer subunit vaccine \"Grippol\". Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1998;3:40‐3. CENTRAL\n\nGoogle Scholar\n\nFeldman S, Wright PF, Webster RG, Roberson PK, Mahoney J, Thompson J, et al. Use of influenza A virus vaccines in seronegative children: live cold‐adapted versus inactivated whole virus. Journal of Infectious Diseases 1985;152(6):1212‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nFoy HM, Cooney MK, Allan ID, Frost F, Blumhagen JM, Fox JP. Influenza B virus vaccines in children and adults: adverse reactions, immune response, and observations in the field. Journal of Infectious Diseases 1981;143(5):700‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nFrance EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, et al. Safety of the trivalent inactivated influenza vaccine among children: a population‐based study. Archives of Pediatric and Adolescent Medicine 2004;158:1031‐6. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nFujieda M, Maeda A, Kondo K, Fukushima W, Ohfuji S, Kaji M, et al. Influenza vaccine effectiveness and confounding factors among young children. Vaccine 2008;26(50):6481‐5. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, et al. Direct and total effectiveness of the intranasal, live‐attenuated, trivalent cold‐adapted influenza virus vaccine against the 2000‐2001 influenza A(H1N1) and B epidemic in healthy children. Archives of Pediatric and Adolescent Medicine 2004;158(1):65‐73. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nGendon IuZ, Kaira AN, El'shina GA, Akhmadulina RR. Total immunization of children against influenza decreases morbidity in a number of diseases among elderly persons during influenza epidemic. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2004;5:62‐7. CENTRAL\n\nGoogle Scholar\n\nGlezen WP. Effectiveness of influenza vaccination of day care children in reducing influenza‐related morbidity among household contacts. Journal of Pediatrics 2001;138:782. CENTRAL\n\nGoogle Scholar\n\nGroothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutinin antigen in very young high‐risk children. Vaccine 1994;12(2):139‐41. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGroothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP‐2) vaccine in seropositive children with bronchopulmonary dysplasia. Journal of Infectious Diseases 1998;177(2):467‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one‐ and two‐dose trials in children: a summary. Journal of Infectious Diseases 1977;136(Suppl):616‐25. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nGross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double‐blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole‐virus and split‐product influenza vaccines in children. Journal of Infectious Diseases 1977;136(5):623‐32. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGross PA, Quinnan GV, Gaerlan PF, Denning CR, Davis A, Lazicki M, et al. Potential for single high‐dose influenza immunization in unprimed children. Pediatrics 1982;70(6):982‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGruber WC, Kirschner K, Tollefson S, Thompson J, Reed G, Edwards KM, et al. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. Journal of Infectious Diseases 1993;168(1):53‐60. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHaba‐Rubio J, Rossetti AO, Tafti M, Heinzer R. Narcolepsy with cataplexy associated with H1N1 vaccination [Narcolepsie avec cataplexie a pres vaccination anti‐H1N1]. Revista de Neurologia 2011;167(8‐9):563‐6. CENTRAL\n\nGoogle Scholar\n\nHalperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture‐derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002;20(7‐8):1240‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHambidge SJ, Glanz JM, France EK. Safety of inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006;296:1990‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHatch LA, Hawkins GF, McDonald JC. Influenza vaccination in a residential boys' school; report to the medical research council committee on clinical trials of influenza vaccine. British Medical Journal 1956;12(5003):1200‐2. CENTRAL\n\nGoogle Scholar\n\nHeikkinen T, Ziegler T, Peltola V, Lehtinen P, Toikka P, Lintu M, et al. Incidence of influenza in Finnish children. Pediatic Infectious Disease Journal 2003;22(Suppl 10):204‐6. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nHoskins TW, Davies JR, Allchin A, Miller CL, Pollock TM. Controlled trial of inactivated influenza vaccine containing the a‐Hong Kong strain during an outbreak of influenza due to the a‐England‐42‐72 strain. Lancet 1973;2(7821):116‐20. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza‐A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979;1(8106):33‐5. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHowell RW, MacKenzie AB. A comparative trial of oil‐adjuvant and aqueous polyvalent influenza vaccines. British Journal of Industrial Medicine 1964;21:265‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHowell RW, Stott AN. A trial of oil‐adjuvant influenza vaccine in a non‐epidemic season. British Journal of Industrial Medicine 1964;21:259‐64. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHrabar A, Vodopija I, Andre FE, Mitchell JR, Maassab HF, Hennessy AV, et al. A placebo‐controlled dose‐response study of the reactogenicity and immunogenicity of a cold‐adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Developments in Biological Standardization 1977;39:53‐60. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nHurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, et al. Effectiveness of influenza vaccination of day care children in reducing influenza‐related morbidity among household contacts. JAMA 2000;284(13):1677‐82. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nHurwitz ES, Haber M, Chang A, Shope T, Teo ST, Giesick JS, et al. Studies of the 1996‐1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. Journal of Infectious Diseases 2000;182:1218‐21. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJansen AG, Sanders EA, Hoes AW, Van Loon AM, Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double‐blind, placebo‐controlled trial. Journal of Pediatrics 2008;153(6):764‐70. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJovanovic D, Georges‐Delvaux AM, Delem A. Protective efficacy of live influenza vaccines. Its assessment in field and experimental conditions. Developments in Biological Standardization 1979;43:241‐5. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nJurgenssen O, Moritz A, Liehl E, Bachmayer H. Vaccination of infants and schoolchildren with an influenza subunit vaccine (author's translation). Infection 1978;6(5):221‐7. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nJust M, Burgin‐Wolff A, Berger‐Hernandez R, Bachlin A, Ritzel G, Moritz AJ. A/New Jersey/76 influenza vaccine trial in seronegative schoolchildren: comparison of a subunit vaccine with a whole‐virus vaccine. Medical Microbiology and Immunology 1978;164(4):277‐84. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKarron RA, Steinhoff MC, Subbarao EK, Wilson MH, Macleod K, Clements ML, et al. Safety and immunogenicity of a cold‐adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatric Infectious Disease Journal 1995;14(1):10‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKaufman Z, Cohen‐Manheim I, Green MS. Compliance with influenza vaccination in Israel in two successive winters, 1998/1999 and 1999/2000. Israel Medical Association Journal 2000;2(10):742‐5. CENTRAL\n\nGoogle Scholar\n\nKing JC, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold‐adapted, live attenuated influenza vaccine administered to human immunodeficiency virus‐infected and noninfected children. Pediatric Infectious Disease Journal 2001;20(12):1124‐31. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I‐MOVE, a multicentre case‐control study. Eurosurveillance 2011;16:11. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nKramarz P, Destefano F, Gargiullo PM, Chen RT, Lieu TA, Davis RL, et al. Does influenza vaccination prevent asthma exacerbations in children?. Journal of Pediatrics 2001;138(3):306‐10. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKuno‐Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, Fukumi H. Developments in mucosal influenza virus vaccines. Vaccine 1994;12(14):1303‐10. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLa Montagne JR, Noble GR, Quinnan GV, Curlin GT, Blackwelder WC, Smith JI, et al. Summary of clinical trials of inactivated influenza vaccine ‐ 1978. Reviews of Infectious Diseases 1983;5(4):723‐36. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLauteria SF, Kantzler GB, High PC, Lee JD, Waldman RH. An attenuated influenza virus vaccine: reactogenicity, transmissibility, immunogenicity, and protective efficacy. Journal of Infectious Diseases 1974;130(4):380‐3. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLerman SJ. Reactivity and immunogenicity of monovalent A/New Jersey/76 influenza virus vaccines in children. Journal of Infectious Diseases 1977;136(Suppl):563‐70. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nLina B, Fletcher MA, Valette M, Saliou P, Aymard M. A TritonX‐100‐split virion influenza vaccine is safe and fulfills the Committee for Proprietary Medicinal Products (CPMP) recommendations for the European Community for immunogenicity, in children, adults and the elderly. Biologicals 2000;28(2):95‐103. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLongini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two‐year, multi‐center vaccine trial: implications for influenza epidemic control. Vaccine 2000;18(18):1902‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLuce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, et al. Cost‐effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001;108(2):e24. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLuthardt T, Lutz O, Kindt H. Immunisation against influenza with a new subunit vaccine tested on children at risk (author's translation). Deutsche Medizinische Wochenschrift 1979;10(2):56‐60. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nMadhi S, Cutland C, Jones S, Hugo A, Treurnicht FK, Kuwanda L, et al. Randomized, placebo‐controlled trial on safety and efficacy of inactivated influenza vaccination of pregnant women in preventing illness in their infants. International Journal of Infectious Diseases 2014;21:32. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nMarchisio P, Cavagna R, Maspes B, Gironi S, Esposito S, Lambertini L, et al. Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children. Clinical Infectious Diseases 2002;35(2):168‐74. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMartín Moreno V, Molina Cabrerizo MR, Sotillo Rincón MJ, Gómez Gómez C, Alvarez Gómez J. Adverse effects associated with influenza vaccine in pediatrics. Revista Española de Salud Pública 1998;72:319‐29. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMaynard JE, Dull HB, Hanson ML, Feltz ET, Berger R, Hammes L. Evaluation of monovalent and polyvalent influenza vaccines during an epidemic of type A2 and B influenza. American Journal of Epidemiology 1968;87(1):148‐57. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMcMahon AW, Iskander JK, Haber P, Braun MM, Ball R. Inactivated influenza vaccine (IIV) in children < 2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal‐free or thimerosal‐containing vaccine. Vaccine 2008;26(3):427‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold‐adapted (CAIV‐T) in healthy children and healthy adults. Vaccine 2001;19(17‐9):2221‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMonto AS, Davenport FM, Napier JA, Francis T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. Journal of Infectious Diseases 1970;122(1):16‐25. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMonto AS, Maassab HF. Use of influenza vaccine in non‐high risk populations. Developments in Biological Standardization 1977;39:329‐35. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nMorio S, Okamoto N, Kawamoto A, Suyama A, Okamoto M, Nakayama H. Three year follow‐up study of national influenza vaccination practices in Japan. Journal of Epidemiology and Community Health 1994;48(1):46‐51. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMorris CA, Freestone DS, Stealey VM. Natural challenge of subjects vaccinated with WRL 105 strain live influenza vaccine in a residential community. Developments in Biological Standardization 1976;33:197‐201. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nMuhammad RD, Haber P, Broder KR, Leroy Z, Ball R, Braun MM, et al. Adverse events following trivalent inactivated influenza vaccination in children: analysis of the Vaccine Adverse Event Reporting System. Pediatric Infectious Disease Journal 2011;30(1):e1‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nNeuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold‐adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatric Infectious Disease Journal 2001;20(8):733‐40. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nNeuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine‐naive 5‐8‐year‐old children. Journal of Infectious Diseases 2006;194:1032‐9. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nNolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, et al. Safety and immunogenicity of a live‐attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 2003;21(11‐2):1224‐31. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nOgra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, et al. Clinical and immunologic evaluation of neuraminidase‐specific influenza A virus vaccine in humans. Journal of Infectious Diseases 1977;135(4):499‐506. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nPiedra PA, Glezen PW. Influenza in children: epidemiology, immunity, and vaccines. Seminars in Pediatric Infectious Diseases 1991;2(2):140‐6. CENTRAL\n\nGoogle Scholar\n\nPiedra PA, Glezen WP, Mbawuike I, Gruber WC, Baxter BD, Boland FJ, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine 1993;11(7):718‐24. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nPiedra PA. Safety of the trivalent, cold‐adapted influenza vaccine (CAIV‐T) in children. Seminars in Pediatric Infectious Diseases 2002;13(2):90‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nQuach C, Piche‐Walker L, Platt R, Moore D. Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy. Pediatrics 2003;112(3 Pt 1):e197‐201. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nRimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000;19(9‐10):1180‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nRuben FL, Akers LW, Stanley ED, Jackson GG. Protection with split and whole virus vaccines against influenza. Archives of Internal Medicine 1973;132(4):568‐71. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSchaad UB, Buhlmann U, Burger R, Ruedeberg A, Wilder‐Smith A, Rutishauser M, et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2000;44(5):1163‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nScheifele DW, Bjornson G, Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. Canadian Medical Association Journal 1990;142(2):127‐30. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nSchiff GM, Linnemann CC, Shea L, Lange B, Rotte T. Evaluation of a live, attenuated recombinant influenza vaccine in high school children. Infection and Immunity 1975;11(4):754‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSlepushkin AN, Obrosova‐Serova NP, Burtseva EI, Rudenko LG, Govorkova EA, Vartanyan RV, et al. Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88. Vaccine 1993;11(3):323‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nStowe J, Andrews N, Bryan P, Seabroke S, Miller E. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study. Vaccine 2011;29(51):9467‐72. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well‐matched type B. JAMA 1994;272(14):1122‐6. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nSumaya CV, Brunell PA. A clinical trial with monovalent influenza A/New Jersey/76 virus vaccine in preschool and school‐age children. Journal of Infectious Diseases 1977;Suppl 136:597‐600. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nVan Hoecke C, Raue W, Kunzel W, Engelmann H. Immunogenicity and safety of influenza vaccination in 3‐ to 6‐year‐old children with a two dose immunisation schedule. European Journal of Pediatrics 1996;155(4):346‐7. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nVasil'eva RI, Liamtseva GA, Riazantseva TG, Oleinikova EV, Sosunov AV. Assessment of the prophylactic effectiveness of an inactivated influenza vaccine by immunizing schoolchildren in the springtime. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1986;3:10‐4. CENTRAL\n\nGoogle Scholar\n\nVasil'eva RI, Lonskaia NI, Nefedova LA, Iaroshevskaia II, Bichurina MA. Results of a study of new preparations of inactivated whole‐virion influenza vaccines for the protection of children in the USSR. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1987;3:38‐42. CENTRAL\n\nGoogle Scholar\n\nWahlberg J, Fredriksson J, Vaarala O, Ludvigsson J. Vaccinations may induce diabetes‐related autoantibodies in one‐year‐old children. Annals of the New York Academy of Sciences 2003;1005:404‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWelty PB, Epstein B, O'Brien J, Brackett RG, Brandon FB, Shillis JL. Reactions and serologic responses after administration of inactivated monovalent influenza A/swine virus vaccines. II. Immunization of children with influenza A/New Jersey/X‐53 virus vaccines. Journal of Infectious Diseases 1977;136(Suppl):609‐11. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWelty PB, Epstein B, O'Brien J, Brackett RG, Brandon FB, Shillis JL. Reactions and serologic responses after administration of inactivated monovalent influenza A/swine virus vaccines. I. Immunization of children and adults with influenza A/Shope virus vaccines. Journal of Infectious Diseases 1977;136(Suppl):604‐8. CENTRAL\n\nLink to article\n\nGoogle Scholar\n\nWesselius‐de Casparis A, Masurel N, Kerrebijn KF. Field trial with human and equine influenza vaccines in children: protection and antibody titres. Bulletin of the World Health Organization 1972;46(2):151‐7. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nWright PF, Dolin R, La Montagne JR. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines‐II. Journal of Infectious Diseases 1976;134:633‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWright PF, Bhargava M, Johnson PR, Thompson J, Karzon DT. Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes. Vaccine 1985;3(3):305‐8. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWu J, Xu F, Lu L, Lu M, Miao L, Gao T, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. New England Journal of Medicine 2010;363(25):2416‐23. CENTRAL\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nZhilova GP, Ignat'eva GS, Orlov VA, Malikova EV, Maksakova VL. Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980‐1983). Voprosy Virusologii 1986;31(1):40‐4. CENTRAL\n\nPubMed\n\nGoogle Scholar\n\nAdditional references\n\nJump to:\n\nAmerican Academy of Pediatrics Committee on Infectious Diseases. Recommendations for influenza immunization of children. Pediatrics 2004;113:1441‐7.\n\nLink to article\n\nPubMed\n\nGrohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and control of seasonal influenza with vaccines. Morbidity and Mortality Weekly Report 2016;65(5):1‐54.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nAmbrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta‐analysis of 8 randomized controlled studies. Vaccine 2012;30(5):886‐92.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nAtkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.\n\nPubMed\n\nGoogle Scholar\n\nBelshe RB, Toback SL, Yi T, Ambrose CS. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza and Other Respiratory Viruses 2010;4(3):141‐5.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nBroome C, Facklam R, Fraser D. Pneumococcal disease after pneumococcal vaccination ‐ an alternative method to estimate the efficacy of pneumococcal vaccine. New England Journal of Medicine 1980;303(10):549‐52.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nCarter NJ, Curran MP. Live attenuated influenza vaccine (FluMist; Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011;71(12):1591‐622.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nFiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. Morbidity and Mortality Weekly Report 2007;56(RR‐6):1‐54.\n\nPubMed\n\nGoogle Scholar\n\nCenters for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. Morbidity and Mortality Weekly Report 2011;60(33):1128‐32.\n\nPubMed\n\nCollignon P, Doshi P, Jefferson T. Ramifications of adverse events in children in Australia (letter to the Editor). BMJ 2010;340:c2994.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nCowling B, Fang V, Nishiura H, Chan K‐H, Ng S, Ip DKM, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. Clinical Infectious Diseases 2012;54(12):1778‐83.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nDemicheli V, Jefferson T, Di Pietrantonj C, Al‐Ansary LA, Ferroni E, Thorning S, et al. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD004876.pub3]\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nDemicheli V, Jefferson T, Al‐Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD001269.pub5]\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nEuropean Centre for Disease Prevention and Control. Protocol for case‐control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States ‐ Technical Document. ecdc.europa.eu/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf (accessed prior to 23 January 2018).\n\nEuropean Medicines Agency. EMA/CHMP/VWP/457259/2014. Committee for Medicinal Products for Human Use. Guideline on influenza vaccines. Non‐clinical and clinical module. www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500211324 (accessed prior to 23 January 2018).\n\nFiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report 2010;59(RR‐8):1‐62.\n\nPubMed\n\nGoogle Scholar\n\nFoppa IM, Haber M, Ferdinands JM, Shay DK. The case test‐negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013;31(30):3104‐9.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nForrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture‐confirmed influenza virus in young children. Clinical and Vaccine Immunology 2008;15(7):1042‐53.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nGRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014.\n\nHarper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2004;53(RR‐6):1‐40.\n\nPubMed\n\nGoogle Scholar\n\nHiggins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.\n\nIoannidis JPA, Manzoli L, De Vito C, D’Addario M, Villari P. Publication delay of randomized trials on 2009 Influenza A (H1N1) vaccination. PLoS ONE 2011;6(12):e28346. [DOI: 10.1371/journal.pone.0028346]\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nIzurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. New England Journal of Medicine 2000;342:232‐9.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJefferson T, Smith S, Demicheli V, Harnden A, Rivetti A. Safety of influenza vaccines in children. Lancet 2005;366(9488):803‐4.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Study quality, concordance, take home message, funding and impact: their relationship in influenza vaccines studies. BMJ 2009;338:b354.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al‐Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD001269.pub4]\n\nLink to article\n\nGoogle Scholar\n\nJefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD004879.pub4]\n\nLink to article\n\nGoogle Scholar\n\nJordan R, Connock M, Albon E, Fry‐Smith A, Olowokure B, Hawker J, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 2006;24(8):1047‐62.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nKissling E, Rondy M, I‐MOVE/I‐MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I‐MOVE multicentre case control studies at primary care and hospital levels in Europe. Eurosurveillance 2017;22(7):30464. [DOI: 10.2807/1560‐7917.ES.2017.22.7.30464]\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLoeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJD, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010;303(10):943–50.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nLum LC, Borja‐Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010;28(6):1566‐74.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nManzoli L, Schioppa F, Boccia A, Villari P. The efficacy of influenza vaccine for healthy children: a meta‐analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatric Infectious Disease Journal 2007;26(2):97‐106.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nManzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JPA. Meta‐analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS ONE 2011;6(9):e24384.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nMereckiene J, Cotter S, D’Ancona F, Giambi C, Nicoll A, Levy‐Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008‐2009. Eurosurveillance 2010;15(44):1‐10.\n\nLink to article\n\nGoogle Scholar\n\nMichiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011;29(49):9159‐70.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nNegri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta‐analysis. Vaccine 2005;23(22):2851‐61.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nNeuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. New England Journal of Medicine 2000;342:225‐31.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nOrenstein W, Bernier R, Dondero T, Hinman AR, Marks JS, Bart KJ, et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization 1985;63(6):1055‐68.\n\nPubMed\n\nGoogle Scholar\n\nOrr P. Statement on influenza vaccination for the 2004‐2005 season. Canada Communicable Disease Report 2004;30:1‐32.\n\nPubMed\n\nGoogle Scholar\n\nOsterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta‐analysis. Lancet 2012;12(1):36‐44.\n\nLink to article\n\nGoogle Scholar\n\nPerencevich EN. Pondering vexing issues in infection prevention and control. haicontroversies.blogspot.com.au/2015/09/there‐is‐no‐such‐thing‐as‐patient‐safety.html#!/ (accessed 22 May 2017).\n\nPerencevich EN. How should we calculate influenza vaccine effectiveness? ACP Internist Blog Archive. blog.acpinternist.org/2013/02/how‐should‐we‐calculate‐influenza_7.html (accessed 17 May 2017).\n\nPrincipi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics?. Lancet 2004;4:75‐83.\n\nLink to article\n\nGoogle Scholar\n\nReichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. New England Journal of Medicine 2001;344:889‐96.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nNordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.\n\nRhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, et al. Efficacy of live attenuated influenza vaccine in children: a meta‐analysis of nine randomized clinical trials. Vaccine 2009;27(7):1101‐10.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nRodrigo Pendas JA, Alemany Vilches L, Moraga Llop FA. Systematic reviews of the efficacy and effectiveness of influenza vaccination in infants, children and teenagers [Revisiones sistematicas de la eficacia o efectividad de las vacunas antigripales en el lactante, el nino y el adolescente sano]. Vacunas 2007;8(3):130‐42.\n\nGoogle Scholar\n\nNational Institute for Health and Welfare (THL). National Narcolepsy Task Force Interim Report. www.thl.fi/thl‐client/pdfs/dce182fb‐651e‐48a1‐b018‐3f774d6d1875 (accessed 2 January 2012).\n\nTreanor JJ. Influenza vaccination. New England Journal of Medicine 2016;375(13):1261‐8. [DOI: 10.1056/NEJMcp1512870]\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nValenciano M, Ciancio BC, I‐MOVE study team. I‐MOVE: a European network to measure the effectiveness of influenza vaccine. Eurosurveillance 2012;17(39):20281.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWijnans L, De Bie S, Dieleman J, Bonhoeffer J, Sturkenboom M. Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine 2011;29(43):7559‐71.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. Influenza and Other Respiratory Viruses 2016;10(1):2‐8.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nWiselka M. Influenza: diagnosis, management and prophylaxis. BMJ 1994;308(6940):1341‐5.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nYin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis. Influenza and Other Respiratory Viruses 2011;5(5):299‐305.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nReferences to other published versions of this review\n\nJump to:\n\nJefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005;365(9461):773‐80.\n\nLink to article\n\nPubMed\n\nGoogle Scholar\n\nJefferson T, Rivetti A, Harnden AR, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004879.pub3]\n\nLink to article\n\nGoogle Scholar\n\nJefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004879.pub4]\n\nLink to article\n\nGoogle Scholar\n\nSmith S, Demicheli V, Jefferson T Harnden A, Matheson N, Di Pietrantonj C. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004879]\n\nLink to article\n\nGoogle Scholar\n\nSmith S, Demicheli V, Di Pietrantonj C, Harnden AR, Jefferson T, Matheson NJ, et al. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004879.pub2]\n\nLink to article\n\nGoogle Scholar\n\nCharacteristics of studies\n\nCharacteristics of included studies [author‐defined order]\n\nJump to:\n\nab Aksenov 1971\n\naa Alexandrova 1986\n\nca Allison 2006\n\nba Anonymous 2005\n\nab Belshe 1992\n\naa Belshe 1998\n\naa Belshe 2000a\n\naa Beutner 1979a\n\naa Beutner 1979b\n\nca Burtseva 1991\n\nca Chumakov 1987\n\naa Clover 1991\n\naa Colombo 2001\n\nab Desheva 2002\n\nca El'shina 2000\n\nca Fujieda 2006\n\nbb Goodman 2006\n\nab Grigor'eva 1994\n\naa Grigor'eva 2002\n\naa Gruber 1990\n\nab Gruber 1996\n\nab Gruber 1997\n\nab Gutman 1977\n\nba Hirota 1992\n\naa Hoberman 2003a\n\naa Hoberman 2003b\n\nca Jianping 1999\n\nca Kawai 2003\n\naa Khan 1996\n\nab King 1998\n\nca King 2006\n\nab Levine 1977\n\nca Maeda 2002\n\nca Maeda 2004a\n\nca Maeda 2004b\n\nca Maeda 2004c\n\ncb Nicholls 2004\n\nab Obrosova‐Serova 1990\n\nca Ozgur 2006\n\naa Principi 2003\n\ncb Ritzwoller 2005\n\naa Rudenko 1988\n\nab Rudenko 1991\n\naa Rudenko 1993a\n\naa Rudenko 1993b\n\nMethods\n\nSee Rudenko 1993a\n\nParticipants\n\nInterventions\n\nOutcomes\n\nFunding Source\n\nNotes\n\nRisk of bias\n\nBias\n\nAuthors' judgement\n\nSupport for judgement\n\nRandom sequence generation (selection bias)\n\nUnclear risk\n\nNo description\n\nAllocation concealment (selection bias)\n\nHigh risk\n\nNot used\n\nBlinding (performance bias and detection bias)\n\nAll outcomes\n\nUnclear risk\n\nNot used\n\nIncomplete outcome data (attrition bias)\n\nAll outcomes\n\nUnclear risk\n\nNo description\n\nSummary assessments\n\nHigh risk\n\naa Rudenko 1996a\n\naa Rudenko 1996b\n\nca Salleras 2006\n\nab Slepushkin 1974\n\nab Slepushkin 1988\n\nab Slepushkin 1991\n\ncb Slepushkin 1994\n\nca Slobodniuk 2002a\n\nca Slobodniuk 2002b\n\nMethods\n\nSee Slobodniuk 2002a\n\nParticipants\n\nInterventions\n\nOutcomes\n\nFunding Source\n\nNotes\n\nRisk of bias\n\nBias\n\nAuthors' judgement\n\nSupport for judgement\n\nPCS/RCS‐Selection Exposed cohort\n\nUnclear risk\n\nNot described\n\nPCS/RCS‐Selection Non Exposed cohort\n\nUnclear risk\n\nNot described\n\nPCS/RCS‐Comparability\n\nUnclear risk\n\nNot described\n\nPCS/RCS‐Assessment of Oucome\n\nUnclear risk\n\nNot described\n\nSummary assessments\n\nHigh risk\n\nInsufficient information to assess study design\n\nca Slobodniuk 2002c\n\nMethods\n\nSee Slobodniuk 2002a\n\nParticipants\n\nInterventions\n\nOutcomes\n\nFunding Source\n\nNotes\n\nRisk of bias\n\nBias\n\nAuthors' judgement\n\nSupport for judgement\n\nPCS/RCS‐Selection Exposed cohort\n\nUnclear risk\n\nNot described\n\nPCS/RCS‐Selection Non Exposed cohort\n\nUnclear risk\n\nNot described\n\nPCS/RCS‐Comparability\n\nUnclear risk\n\nNot described\n\nPCS/RCS‐Assessment of Oucome\n\nUnclear risk\n\nNot described\n\nSummary assessments\n\nHigh risk\n\nInsufficient information to assess study design\n\nab Steinhoff 1990\n\nab Steinhoff 1991\n\nab Swierkosz 1994\n\naa Tam 2007a\n\nca Vasil'eva 1982\n\nab Vasil'eva 1988a\n\nab Vasil'eva 1988b\n\naa Vesikari 2006a\n\naa Vesikari 2006b\n\nca Wiggs‐Stayner 2006\n\nab Wright 1976a\n\nab Zangwill 2001\n\naa Bracco Neto 2009a\n\nba Cochran 2010a\n\nba Eisenberg 2008a\n\nba Gilca 2011\n\nba Kelly 2011\n\nba Kissling 2011\n\nba Mahmud 2011\n\nab Mallory 2010\n\nca Ortqvist 2011\n\nab Plennevaux 2011\n\nba Staat 2011a\n\nba Valenciano 2011\n\nba Van Buynder 2010\n\nca Yin 2011\n\ncb MPA 2011\n\naa Bracco Neto 2009b\n\nba Eisenberg 2008b\n\naa Tam 2007b\n\nba Cochran 2010b\n\nba Cochran 2010c\n\nba Staat 2011b\n\naa Brooks 2016\n\naa Cowling 2012\n\nMethods\n\nCluster‐randomised, placebo‐controlled trial conducted in Hong Kong between 2009 and 2010\n\nParticipants\n\n796 children aged 6 to 17 in households\n\nInterventions\n\nTIV (0.5 mL of Vaxigrip; Sanofi Pasteur) or placebo (0.5 mL of saline solution) intramuscularly. The 2009–10 TIV used included the strains A/Brisbane/59/2007(H1N1)‐like, A/Brisbane/10/ 2007(H3N2)‐like, and B/Brisbane/60/2008‐like.\n\nOutcomes\n\nInfluenza cases laboratory confirmed by viral culture and/or real‐time reverse transcription PCR or 4 fold in antibody titre. Mild, moderate, or severe adverse events recorded by parents for 4 days after vaccination.\n\nFunding Source\n\nHong Kong Government\n\nNotes\n\nRisk of bias\n\nBias\n\nAuthors' judgement\n\nSupport for judgement\n\nRandom sequence generation (selection bias)\n\nLow risk\n\nGroups of children allocated to vaccine or control group\n\nAllocation concealment (selection bias)\n\nLow risk\n\nComputer‐generated random numbers\n\nBlinding (performance bias and detection bias)\n\nAll outcomes\n\nLow risk\n\nNumbered, identical‐looking syringes\n\nIncomplete outcome data (attrition bias)\n\nAll outcomes\n\nHigh risk\n\nFailure to report numerator numbers\n\nSummary assessments\n\nLow risk\n\nCharacteristics of excluded studies [ordered by study ID]\n\nJump to:\n\nStudy\n\nReason for exclusion\n\nAmbrose 2011\n\nPooled analysis of safety data from 20 RCTs of LAIV\n\nAmbrose 2014\n\nReview of evidence of effects of LAIV different disease severity. No primary data fitting inclusion criteria reported.\n\nAnderson 1992\n\nOnly serological outcomes presented.\n\nAnonymous 2003\n\nEditorial only\n\nBeare 1968\n\nStudy participants were adults.\n\nBelshe 2000b\n\nOnly serological outcomes presented.\n\nBelshe 2000c\n\nOnly aggregated outcomes presented, duplicate publication of Belshe 1998 and 2000.\n\nBelshe 2008\n\nData from studies already included in review\n\nBergen 2004\n\nOutcomes only presented if statistically significantly increased or decreased risk in vaccinated group. Outcomes were presented by age group and setting. Authors declined to grant access to data from settings and age groups where outcomes were not significantly different between treatment and control.\n\nBetts 1977\n\nStudy participants were university students aged 18 to 25.\n\nBeutner 1976\n\nSame study as Beutner 1979 (included)\n\nBichurina 1982\n\nNo denominators presented.\n\nBlock 2011\n\nNon‐inferiority study\n\nBoyce 1999\n\nNo clinical outcomes for efficacy and safety\n\nBoyce 2000\n\nStudy population aged 18 to 40\n\nBoyer 1977\n\nOnly serological outcomes were presented.\n\nCakir 2012\n\nStudy design inconsistent (randomised case control study)\n\nChow 1979\n\nSerological study on part of study population of Beutner 1979\n\nClements 1995\n\nHepatitis B vaccine as control\n\nColes 1992\n\nStudy population consisted of elderly and staff from nursing home.\n\nCowling 2014\n\nIncidence data derived from an RCT published elsewhere\n\nDaubeney 1997\n\nHigh‐risk children\n\nDonatelli 1998\n\nNo control (split vaccine versus trivalent subunit‐type)\n\nEddy 1970\n\nParticipants were healthy adult males.\n\nEdwards 1994\n\nPlacebo arm present only in the first study year, for which neither efficacy nor safety data are available.\n\nAge group is 1 to 65 years, and no data are presented for children only.\n\nEl'shina 1998\n\nAge group 18 to 23\n\nFeldman 1985\n\nOnly serological outcomes presented.\n\nFoy 1981\n\nNo control\n\nFrance 2004\n\nCase cross‐over\n\nFujieda 2008\n\nSame data of Fujieda 2006 (included)\n\nGaglani 2004\n\nEcological study\n\nGendon 2004\n\nStudy addresses the question of whether vaccinating children interrupts transmission to elderly. Study should be included in the elderly review.\n\nGlezen 2001\n\nComment only (on Hurwitz 2000a)\n\nGroothuis 1994\n\nStudy participants were children with chronic pulmonary diseases; no control.\n\nGroothuis 1998\n\nTrial of respiratory syncytial virus vaccine\n\nGross 1977a\n\nOnly serological outcomes\n\nGross 1977b\n\nNo placebo control\n\nGross 1982\n\nAll recipients had cystic fibrosis.\n\nGruber 1993\n\nFollow‐up times for safety outcomes variable within groups. Total follow‐up time not stated in Methods, refers to other papers for methodology.\n\nHaba‐Rubio 2011\n\nCase report of cases of narcolepsy\n\nHalperin 2002\n\nStudy participants had chronic cardiac or pulmonary disorders.\n\nHambidge 2006\n\nCase cross‐over study\n\nHatch 1956\n\nNo control\n\nHeikkinen 2003\n\nSurvey carried out on children younger than 13 years to determine the attack of flu virus in those having fever or respiratory infections\n\nHoskins 1973\n\nNo placebo control; excluded because an influenza B vaccine was used as control\n\nHoskins 1979\n\nNo control\n\nHowell 1964a\n\nAdult population\n\nHowell 1964b\n\nAdult population\n\nHrabar 1977\n\nLikely that more than 25% of the study participants are older than 25 years (mean 15.8; range 14.0 to 17.9); efficacy outcomes only serological\n\nHurwitz 2000a\n\nHepatitis A vaccine as control\n\nHurwitz 2000b\n\nHepatitis A vaccine as control\n\nJansen 2008\n\nHead‐to‐head: TIV+PCV7 vs TIV+PLA vs HBV+PLA\n\nJovanovic 1979\n\nNon‐experimental design\n\nJurgenssen 1978\n\nNo placebo control\n\nJust 1978\n\nNo placebo control\n\nKarron 1995\n\nInfluenza vaccine administered with routine immunisation.\n\nKaufman 2000\n\nTelephone survey to estimate the compliance rate with influenza vaccination\n\nKing 2001\n\nStudy included HIV‐infected groups and uninfected groups; uninfected groups excluded because trial was a cross‐over design; safety data for 1st, 2nd, and 3rd doses were pooled so could not be used (some placebo recipients would have received vaccine 4 to 5 weeks previously, and participants would be included in N for placebo and vaccine).\n\nKissling 2011a\n\nData already presented in Kissling 2011.\n\nKramarz 2001\n\nStudy participants are children with asthma.\n\nKuno‐Sakai 1994\n\nStudy participants are aged 16 to 17 years. No control\n\nLa Montagne 1983\n\nNo original data presented.\n\nLauteria 1974\n\nStudy population aged 18 to 24 years.\n\nLerman 1977\n\nOnly serological data presented.\n\nLina 2000\n\nNo control\n\nLongini 2000\n\nComment on Belshe 1998 and 2000 only\n\nLuce 2001\n\nCost‐effectiveness analysis based on the results of Belshe 1998 and 2000\n\nLuthardt 1979\n\nNo placebo control\n\nMadhi 2014\n\nResults reported in a study already included in the influenza vaccines in healthy adults review.\n\nMarchisio 2002\n\nStudy participants are children with recurrent otitis media.\n\nMartin Moreno 1998\n\nReview\n\nMaynard 1968\n\nNo placebo control\n\nMcMahon 2008\n\nNon‐comparative study\n\nMendelman 2001\n\nReview\n\nMonto 1970\n\nParticipants vaccinated just before or during epidemic. Vaccine effectiveness expressed as O‐E. No numerator or denominator data reported.\n\nMonto 1977\n\nReview\n\nMorio 1994\n\nOnly cumulative data from 3 years were reported to evaluate effectiveness.\n\nMorris 1976\n\nStudy participants are college students aged 18 to 29.\n\nMuhammad 2011\n\nNon‐comparative study\n\nNeuzil 2001\n\nRe‐analysis of Edwards 1994 (in which placebo arm was present only in the first study year, neither efficacy nor safety data are available)\n\nNeuzil 2006\n\nNon‐comparative study\n\nNolan 2003\n\nNo control (2 different commercial preparations of the same vaccine were compared)\n\nOgra 1977\n\nSame study as Beutner 1979\n\nPiedra 1991\n\n3 studies in 1; 2 already included, the third is of uncertain provenance\n\nPiedra 1993\n\nSafety data are given cumulatively on 3‐year study.\n\nPiedra 2002b\n\nAll the data in this paper are presented in either Piedra 2002 or King 1998 (both included).\n\nQuach 2003\n\nAnalysis of factors associated with hospitalisation\n\nRimmelzwaan 2000\n\nParticipants aged 18 to 55 years\n\nRuben 1973\n\nNo placebo control\n\nSchaad 2000\n\nStudy population consists of children and adolescents with cystic fibrosis.\n\nScheifele 1990\n\nNon‐comparative studies\n\nSchiff 1975\n\nSafety outcomes combined for first and second doses of vaccine\n\nSlepushkin 1993\n\nParticipants received vaccine or placebo depending on their age.\n\nStowe 2011\n\nCase series or case cross‐over\n\nSugaya 1994\n\nStudy participants are children with moderate to severe asthma.\n\nSumaya 1977\n\nOnly serological data are presented.\n\nVan Hoecke 1996\n\nNo control\n\nVasil'eva 1986\n\nNo denominators presented.\n\nVasil'eva 1987\n\nDenominators for vaccinated and placebo groups were combined in results tables.\n\nWahlberg 2003\n\nTrial of Hib vaccine\n\nWelty 1977a\n\nSafety outcomes only with no placebo control\n\nWelty 1977b\n\nSafety outcomes only with no placebo control\n\nWesselius‐de 1972\n\nOnly serological efficacy outcomes presented.\n\nWright 1976b\n\nData duplicated in Wright 1976a.\n\nWright 1985\n\nOnly immune responses and viral shedding outcomes presented.\n\nWu 2010\n\nEfficacy cohort with inadequate follow‐up length\n\nZhilova 1986\n\nStudy population aged 18 to 23\n\nData and analyses\n\nOpen in table viewer\n\nComparison 1. Live vaccine versus placebo (RCTs)\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n7\n\n7718\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.22 [0.11, 0.41]\n\n1.1 Live attenuated vaccines (1 dose)\n\n6\n\n4675\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.28 [0.14, 0.55]\n\n1.2 Live attenuated vaccines (2 doses)\n\n2\n\n3043\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.11 [0.04, 0.26]\n\n2 Influenza‐like illness Show forest plot\n\n7\n\n124606\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.69 [0.60, 0.80]\n\n2.1 Live attenuated vaccines (1 dose)\n\n2\n\n3306\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.64 [0.18, 2.22]\n\n2.2 Live attenuated vaccines (2 doses)\n\n6\n\n121300\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.66 [0.57, 0.76]\n\n3 Otitis media (all episodes) Show forest plot\n\n2\n\n2873\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.98 [0.95, 1.01]\n\n4 School absenteeism Show forest plot\n\n1\n\nRisk Ratio (M‐H, Random, 95% CI)\n\nTotals not selected\n\n5 Working days lost (number of events, parents) Show forest plot\n\n2\n\n2874\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.69 [0.46, 1.03]\n\n6 Drug prescriptions (number of events) Show forest plot\n\n1\n\n1784\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.99 [0.87, 1.12]\n\n7 Outpatients attendance for pneumonia and influenza Show forest plot\n\n2\n\n2874\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.76 [0.59, 0.98]\n\n8 Influenza‐like illness (clustering sensitivity analysis) Show forest plot\n\n7\n\n49666\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.69 [0.59, 0.80]\n\n8.1 Live attenuated vaccines (1 dose)\n\n2\n\n1746\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.64 [0.18, 2.23]\n\n8.2 Live attenuated vaccines (2 doses)\n\n6\n\n47920\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.65 [0.56, 0.76]\n\nOpen in table viewer\n\nComparison 2. Inactivated vaccine versus placebo (RCTs)\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n5\n\n1628\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.36 [0.28, 0.48]\n\n2 Influenza‐like illness Show forest plot\n\n4\n\n19044\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.72 [0.65, 0.79]\n\n2.1 Inactivated vaccines (1 dose)\n\n2\n\n267\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.35 [0.15, 0.81]\n\n2.2 Inactivated vaccines (2 doses)\n\n2\n\n18777\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.72 [0.69, 0.76]\n\n3 Acute otitis media Show forest plot\n\n3\n\n884\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.15 [0.95, 1.40]\n\n3.1 Inactivated vaccines (1 dose)\n\n1\n\n136\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.52 [0.10, 23.76]\n\n3.2 Inactivated vaccines (2 doses)\n\n2\n\n748\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.15 [0.95, 1.40]\n\n4 School absenteeism Show forest plot\n\n1\n\nRisk Ratio (M‐H, Random, 95% CI)\n\nTotals not selected\n\n5 Influenza‐like illness (clustering sensitivity analysis) Show forest plot\n\n4\n\n6126\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.70 [0.60, 0.82]\n\n5.1 Inactivated vaccines (1 dose)\n\n2\n\n267\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.35 [0.15, 0.81]\n\n5.2 Inactivated vaccines (2 doses)\n\n2\n\n5859\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.72 [0.66, 0.79]\n\nOpen in table viewer\n\nComparison 3. Live vaccine versus placebo or no intervention (RCTs by age group)\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n7\n\n10812\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.24 [0.14, 0.41]\n\n1.1 under 2 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n1.2 under 6 years\n\n7\n\n10752\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.22 [0.12, 0.39]\n\n1.3 over 6 years\n\n1\n\n60\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.47 [0.23, 0.97]\n\n2 Influenza‐like illness Show forest plot\n\n8\n\n188418\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.67 [0.62, 0.72]\n\n2.1 under 2 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n2.2 under 6 years\n\n5\n\n38646\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.67 [0.57, 0.77]\n\n2.3 over 6 years\n\n8\n\n149772\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.67 [0.60, 0.74]\n\nOpen in table viewer\n\nComparison 4. Inactivated vaccine versus placebo or no intervention (RCTs by age group)\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n5\n\n1628\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.41 [0.29, 0.59]\n\n1.1 under 2 years\n\n2\n\n786\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.55 [0.18, 1.69]\n\n1.2 under 6 years\n\n2\n\n132\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.61 [0.34, 1.08]\n\n1.3 over 6 years\n\n3\n\n710\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.31 [0.22, 0.45]\n\n2 Influenza‐like illness Show forest plot\n\n5\n\n19388\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.64 [0.54, 0.76]\n\n2.1 under 2 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n2.2 under 6 years\n\n3\n\n476\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.39 [0.21, 0.69]\n\n2.3 over 6 years\n\n4\n\n18912\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.72 [0.66, 0.78]\n\nOpen in table viewer\n\nComparison 5. All vaccine types versus placebo\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n9\n\n8227\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.30 [0.19, 0.45]\n\n1.1 Live attenuated vaccines (1 dose)\n\n5\n\n3556\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.33 [0.18, 0.62]\n\n1.2 Live attenuated vaccines (2 doses)\n\n2\n\n3043\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.11 [0.04, 0.26]\n\n1.3 Inactivated vaccines (1 dose)\n\n5\n\n1628\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.36 [0.28, 0.48]\n\n1.4 Inactivated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n2 Influenza‐like illness Show forest plot\n\n8\n\n143650\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.69 [0.62, 0.77]\n\n2.1 Live attenuated vaccines (1 dose)\n\n2\n\n3306\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.64 [0.18, 2.22]\n\n2.2 Live attenuated vaccines (2 doses)\n\n6\n\n121300\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.66 [0.57, 0.76]\n\n2.3 Inactivated vaccines (1 dose)\n\n2\n\n267\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.35 [0.15, 0.81]\n\n2.4 Inactivated vaccines (2 doses)\n\n2\n\n18777\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.72 [0.69, 0.76]\n\n3 Secondary cases Show forest plot\n\n1\n\n123\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.68 [0.56, 4.99]\n\n3.1 Live attenuated vaccines (1 dose)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n3.2 Live attenuated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n3.3 Inactivated vaccines (1 dose)\n\n1\n\n123\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.68 [0.56, 4.99]\n\n3.4 Inactivated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n4 School absenteeism Show forest plot\n\n1\n\n550\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.49 [0.26, 0.92]\n\n4.1 Live attenuated vaccines (1 dose)\n\n1\n\n296\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.51 [0.22, 1.19]\n\n4.2 Live attenuated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n4.3 Inactivated vaccines (1 dose)\n\n1\n\n254\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.46 [0.17, 1.22]\n\n4.4 Inactivated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n5 Lower respiratory tract disease Show forest plot\n\n2\n\n1632\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.20 [0.03, 1.54]\n\n5.1 Live attenuated vaccines (1 dose)\n\n2\n\n1496\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.16 [0.01, 4.45]\n\n5.2 Live attenuated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n5.3 Inactivated vaccines (1 dose)\n\n1\n\n136\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.30 [0.01, 6.17]\n\n5.4 Inactivated vaccines (2 doses)\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n6 Acute otitis media Show forest plot\n\n6\n\n5253\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.00 [0.79, 1.26]\n\n6.1 Live attenuated vaccines (1 dose)\n\n3\n\n2585\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.42 [0.05, 3.79]\n\n6.2 Live attenuated vaccines (2 doses)\n\n1\n\n1784\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.98 [0.95, 1.01]\n\n6.3 Inactivated vaccines (1 dose)\n\n1\n\n136\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.52 [0.10, 23.76]\n\n6.4 Inactivated vaccines (2 doses)\n\n2\n\n748\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.15 [0.95, 1.40]\n\n7 Hospitalisation due to acute otitis media Show forest plot\n\n2\n\nRisk Ratio (M‐H, Random, 95% CI)\n\nSubtotals only\n\n7.1 Inactivated vaccine (2 doses)\n\n2\n\n765\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n1.41 [0.62, 3.24]\n\n8 Consequences of acute otitis media Show forest plot\n\n2\n\nMean Difference (IV, Random, 95% CI)\n\nSubtotals only\n\n8.1 Inactivated vaccine (2 (doses of the intervention) ‐ visits (outcome measure))\n\n2\n\n765\n\nMean Difference (IV, Random, 95% CI)\n\n‐0.02 [‐0.27, 0.23]\n\n8.2 Inactivated vaccine (2 doses; courses of antibiotics)\n\n2\n\n765\n\nMean Difference (IV, Random, 95% CI)\n\n0.13 [‐0.36, 0.63]\n\n9 Outpatients attendance for pneumonia and influenza Show forest plot\n\n2\n\n2874\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.76 [0.59, 0.98]\n\n9.1 Live attenuated vaccine (1 dose)\n\n1\n\n1090\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.65 [0.49, 0.85]\n\n9.2 Live attenuated vaccine (2 doses)\n\n1\n\n1784\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.85 [0.75, 0.96]\n\n10 Working days lost (number of events, parents of children 6 to 36 months of age) Show forest plot\n\n2\n\n2874\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.69 [0.46, 1.03]\n\n10.1 Live attenuated vaccine\n\n2\n\n2874\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.69 [0.46, 1.03]\n\n11 Drug prescriptions (number of events, 6 to 36 months of age) Show forest plot\n\n1\n\n1784\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.99 [0.87, 1.12]\n\n11.1 Live attenuated vaccine\n\n1\n\n1784\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.99 [0.87, 1.12]\n\nOpen in table viewer\n\nComparison 6. Case‐control studies\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza vs influenza‐like illness (crude data) Show forest plot\n\n9\n\nOdds Ratio (M‐H, Random, 95% CI)\n\nSubtotals only\n\n1.1 Children aged below 6 years\n\n9\n\n4949\n\nOdds Ratio (M‐H, Random, 95% CI)\n\n0.59 [0.45, 0.77]\n\n1.2 Children aged between 5 and 19 years\n\n1\n\n27\n\nOdds Ratio (M‐H, Random, 95% CI)\n\n0.76 [0.07, 8.66]\n\n2 Influenza vs influenza‐like illness (adj. estimates) Show forest plot\n\n9\n\nOdds Ratio (Random, 95% CI)\n\nSubtotals only\n\n2.1 Children aged below 23 months ‐ fully vaccinated\n\n7\n\nOdds Ratio (Random, 95% CI)\n\n0.60 [0.39, 0.94]\n\n2.2 Children aged between 24 and 59 months ‐ fully vaccinated\n\n4\n\nOdds Ratio (Random, 95% CI)\n\n0.40 [0.22, 0.70]\n\n2.3 Children aged between 6 and 59 months ‐ fully vaccinated\n\n5\n\nOdds Ratio (Random, 95% CI)\n\n0.45 [0.32, 0.62]\n\n2.4 Children aged below 14 years old ‐ fully vaccinated\n\n1\n\nOdds Ratio (Random, 95% CI)\n\n0.23 [0.06, 0.84]\n\n3 Influenza‐like illness vs no symptoms Show forest plot\n\n1\n\n488\n\nOdds Ratio (M‐H, Random, 95% CI)\n\n0.49 [0.28, 0.86]\n\n3.1 Inactivated vaccine (1 dose)\n\n1\n\n244\n\nOdds Ratio (M‐H, Random, 95% CI)\n\n0.53 [0.26, 1.07]\n\n3.2 Inactivated vaccine (2 doses)\n\n1\n\n244\n\nOdds Ratio (M‐H, Random, 95% CI)\n\n0.44 [0.18, 1.10]\n\nOpen in table viewer\n\nComparison 7. Live attenuated vaccines (cohort studies by age group)\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n1\n\n83\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.56 [0.35, 0.91]\n\n1.1 under 2 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n1.2 under 6 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n1.3 over 6 years\n\n1\n\n83\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.56 [0.35, 0.91]\n\n2 Influenza‐like illness Show forest plot\n\n2\n\n22077\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.63 [0.57, 0.69]\n\n2.1 under 2 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n2.2 under 6 years\n\n0\n\n0\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.0 [0.0, 0.0]\n\n2.3 over 6 years\n\n2\n\n22077\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.63 [0.57, 0.69]\n\nOpen in table viewer\n\nComparison 8. Inactivated vaccines (cohort studies by age group)\n\nOutcome or subgroup title\n\nNo. of studies\n\nNo. of participants\n\nStatistical method\n\nEffect size\n\n1 Influenza Show forest plot\n\n6\n\n1873\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.42 [0.25, 0.73]\n\n1.1 under 2 years\n\n3\n\n314\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.63 [0.27, 1.47]\n\n1.2 under 6 years\n\n1\n\n180\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.34 [0.13, 0.89]\n\n1.3 over 6 years\n\n2\n\n1379\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.36 [0.12, 1.11]\n\n2 Influenza‐like illness Show forest plot\n\n11\n\n11935\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.53 [0.42, 0.67]\n\n2.1 under 2 years\n\n1\n\n23\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.47 [0.23, 0.93]\n\n2.2 under 6 years\n\n5\n\n7046\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.74 [0.59, 0.93]\n\n2.3 over 6 years\n\n7\n\n4866\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.44 [0.29, 0.68]\n\n3 Otitis media Show forest plot\n\n1\n\n119\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.48 [0.22, 1.03]\n\n3.1 Children aged 6 months to 5 years\n\n1\n\n119\n\nRisk Ratio (M‐H, Random, 95% CI)\n\n0.48 [0.22, 1.03]\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nFigures and Tables -\n\nSummary of findings for the main comparison. Live attenuated influenza vaccine compared to placebo or do nothing for preventing influenza in children\n\nInfluenza vaccine compared to placebo or do nothing for preventing influenza in children\n\nPatient or population: healthy, community‐dwelling children younger than 16 years of age\n\nSetting: influenza seasons in the USA, Western Europe, Russia, and Bangladesh\n\nIntervention: live attenuated influenza vaccine\n\nComparison: placebo or do nothing\n\nOutcomes\n\nAnticipated absolute effects* (95% CI)\n\nRelative effect\n\n(95% CI)\n\n№ of participants\n\n(studies)\n\nQuality of the evidence\n\n(GRADE)\n\nComments\n\nRisk with placebo or do nothing\n\nRisk with influenza vaccine\n\nInfluenza assessed by laboratory confirmation\n\nFollow‐up over 1 or 2 influenza seasons\n\nLow\n\nRR 0.22\n\n(0.11 to 0.41)\n\n7718\n\n(7 RCTs)\n\n⊕⊕⊕⊝\n\nMODERATE2 3\n\n130 per 10001\n\n29 per 1000\n\n(14 to 53)\n\nModerate\n\n180 per 1000\n\n40 per 1000\n\n(20 to 74)\n\nHigh\n\n480 per 1000\n\n106 per 1000\n\n(53 to 197)\n\nInfluenza‐like illness assessed by subjective report\n\nFollow‐up over a single influenza season\n\nLow\n\nRR 0.69\n\n(0.60 to 0.80)\n\n124,606\n\n(7 RCTs)\n\n⊕⊕⊝⊝\n\nLOW4 5\n\n121 per 10001\n\n83 per 1000\n\n(73 to 97)\n\nModerate\n\n172 per 1000\n\n119 per 1000\n\n(103 to 138)\n\nHigh\n\n341 per 1000\n\n235 per 1000\n\n(205 to 273)\n\nOtitis media assessed by clinical confirmation (inspection of ear and symptoms)\n\nFollow‐up over a single influenza season\n\n915 per 1000\n\n897 per 1000\n\n(869 to 924)\n\nRR 0.98 (0.95 to 1.01)\n\n1784\n\n(1 RCT)\n\n⊕⊕⊕⊝\n\nMODERATE6\n\nNumber of children with time off from school during follow‐up\n\nFollow‐up over a single influenza season\n\nStudy population\n\nRR 0.51\n\n(0.22 to 1.19)\n\n296\n\n(1 RCT)\n\n⊕⊝⊝⊝\n\nVERY LOW7 8\n\n100 per 1000\n\n51 per 1000\n\n(22 to 119)\n\nNumber of parents having to take off work during follow‐up\n\nFollow‐up over a single influenza season\n\nStudy population\n\nRR 0.69\n\n(0.46 to 1.03)\n\n2874\n\n(2 RCTs)\n\n⊕⊕⊝⊝\n\nLOW9 1 0\n\n262 per 1000\n\n181 per 1000\n\n(121 to 270)\n\nHospitalisation ‐ not reported\n\n‐\n\n‐\n\n‐\n\n‐\n\n‐\n\nFever assessed as reported increase in temperature\n\nTemperature rise as an outcome was presented in most of the RCTs, with large differences among trials. Considering only studies reporting raw data for this outcome, the proportion of vaccinated children with fever ranged from 0.16% to 15%, while the proportion of children in the placebo groups with fever ranged from 0.71% to 22%.\n\n‐\n\n20,561\n\n(4 RCTs)\n\n⊕⊝⊝⊝\n\nVERY LOW11 12\n\nNausea ‐ not reported\n\n‐\n\n‐\n\n‐\n\n‐\n\n‐\n\n*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).\n\nCI: confidence interval; RCT: randomised controlled trial; RR: risk ratio\n\nGRADE Working Group grades of evidence\n\nHigh quality: We are very confident that the true effect lies close to that of the estimate of the effect.\n\nModerate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.\n\nLow quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.\n\nVery low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.\n\nFigures and Tables -\n\nSummary of findings 2. Inactivated influenza vaccine compared to placebo or do nothing for preventing influenza in children\n\nInactivated influenza vaccine compared to placebo or do nothing for preventing influenza in children\n\nPatient or population: healthy, community‐dwelling children older than 2 years of age\n\nSetting: influenza seasons in the USA\n\nIntervention: inactivated influenza vaccine\n\nComparison: placebo or do nothing\n\nOutcomes\n\nAnticipated absolute effects* (95% CI)\n\nRelative effect\n\n(95% CI)\n\n№ of participants\n\n(studies)\n\nQuality of the evidence\n\n(GRADE)\n\nComments\n\nRisk with placebo or do nothing\n\nRisk with influenza vaccine\n\nInfluenza assessed by laboratory confirmation\n\nFollow‐up over a single influenza season\n\nLow\n\nRR 0.36\n\n(0.28 to 0.48)\n\n1628\n\n(5 RCTs)\n\n⊕⊕⊕⊕\n\nHIGH1\n\n3 per 10001\n\n1 per 1000\n\n(1 to 2)\n\nModerate\n\n298 per 1000\n\n107 per 1000\n\n(83 to 143)\n\nHigh\n\n481 per 1000\n\n173 per 1000\n\n(135 to 231)\n\nInfluenza‐like illness assessed by subjective report\n\nFollow‐up over a single influenza season\n\nLow\n\nRR 0.72\n\n(0.65 to 0.79)\n\n19,044\n\n(4 RCTs)\n\n⊕⊕⊕⊝\n\nMODERATE2\n\n134 per 10001\n\n96 per 1000\n\n(87 to 106)\n\nModerate\n\n282 per 1000\n\n203 per 1000\n\n(183 to 223)\n\nHigh\n\n328 per 1000\n\n236 per 1000\n\n(213 to 259)\n\nOtitis media assessed by clinical confirmation (inspection of ear and symptoms)\n\nFollow‐up over a single influenza season\n\n271 per 1000\n\n312 per 1000\n\n(257 to 379)\n\nRR 1.15\n\n(0.95 to 1.4)\n\n884\n\n(3 RCTs)\n\n⊕⊕⊕⊝\n\nMODERATE3\n\nAbsence from school\n\nFollow‐up over a single influenza season\n\n92 per 1000\n\n42 per 1000\n\n(16 to 112)\n\nRR 0.46\n\n(0.17 to 1.22)\n\n254\n\n(1 RCT)\n\n⊕⊝⊝⊝\n\nVERY LOW4 5\n\nNumber of parents having to take off work during follow‐up ‐ not reported\n\n‐\n\n‐\n\n‐\n\n‐\n\n‐\n\nHospitalisations ‐ not reported\n\n‐\n\n‐\n\n‐\n\n‐\n\n‐\n\nFever ‐ not reported\n\n‐\n\n‐\n\n‐\n\n‐\n\n‐\n\nNausea ‐ not reported\n\n‐\n\n‐\n\n‐\n\n‐\n\n‐\n\n*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).\n\nCI: confidence interval; RCT: randomised controlled trial; RR: risk ratio\n\nGRADE Working Group grades of evidence\n\nHigh quality: We are very confident that the true effect lies close to that of the estimate of the effect.\n\nModerate qual"
    }
}